866-997-4948(US-Canada Toll Free)

Neuropathic Pain - Pipeline Assessment and Market Forecasts to 2016

Published By :

GlobalData

Published Date : Jul 2010

Category :

Therapeutic Area

No. of Pages : 61 Pages


GlobalData, the industry analysis specialists new report, Neuropathic Pain Pipeline Assessment and Market Forecasts to 2016, is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData estimated the global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior and increased uptake of the current products. The diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists unmet needs. There exists a market potential for any new entrant that will cater for these unmet needs. There is enormous opportunity for any drug that could match or better the efficacy provided by the current players with increased safety.

Scope

The scope of the report includes:

  • Annualized global neuropathic pain market revenues data from 2001 to 2009, forecast forward for eight years to 2016.
  • Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists and iNOS/nNOS dual inhibitors.
  • Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc and AstraZeneca.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with neuropathic pain.
Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain the competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunity for consolidations, investments and strategic partnerships.
  • Whats the next big thing in the global neuropathic pain market landscape? Identify, understand and capitalize.
Table Of Contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Global Neuropathic Pain Market: Market Characterization 6
2.1 Overview 6
2.2 Neuropathic Pain Market Size 6
2.3 Neuropathic Pain Market Forecast and CAGR 6
2.4 Drivers and Barriers for Neuropathic Pain Market 8
2.4.1 Drivers for Neuropathic Pain Market 8
2.4.2 Barriers for Neuropathic Pain Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10

3 Global Neuropathic Pain Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Neuropathic Pain Market 12
3.3.1 Lyrica (pregabalin) 12
3.3.2 Cymbalta (duloxetine) 14
3.3.3 Lidoderm (lidocaine patch 5%) 15
3.3.4 Neurontin (gabapentin) 16
3.3.5 Qutenza (capsaicin) 8% Patch 17
3.4 Key Takeaway 20

4 Global Neuropathic Pain Market: Pipeline Assessment 21
4.1 Overview 21
4.2 Strategic Pipeline Assessment 21
4.2.1 Technology Trends Analytic Framework 21
4.3 Neuropathic Pain Therapeutics Promising Drugs under Clinical Development 23
4.4 Molecule Profile for Promising Drugs under Clinical Development 24
4.4.1 Vimpat (lacosamide) 24
4.4.2 Fentora 25
4.4.3 Ralfinamide 26
4.4.4 NP-1 27
4.4.5 Sativex 28
4.5 Neuropathic Pain Therapeutics Market Clinical Pipeline by Mechanism of Action 29
4.6 Neuropathic Pain Pipeline Pipeline by Clinical Phases of Development 30
4.6.1 Neuropathic Pain Therapeutics Regulatory Filing and Phase III Clinical Pipeline 31
4.6.2 Neuropathic Pain Therapeutics Phase II Clinical Pipeline 32
4.6.3 Neuropathic Pain Therapeutics Phase I Clinical Pipeline 34
4.6.4 Neuropathic Pain Therapeutics Preclinical Pipeline 35
4.6.5 Neuropathic Pain Therapeutics Discovery Pipeline 35
4.7 Discontinued / Suspended Drugs for Neuropathic Pain 36
4.8 Key Takeaway 36

5 Global Neuropathic Pain Market: Implications for Future Market Competition 37

6 Global Neuropathic Pain Market: Future Players in Neuropathic Pain Market 39
6.1 Introduction 39
6.2 NeurogesX 40
6.2.1 Overview 40
6.2.2 Pain Portfolio 40
6.2.3 Neuropathic Pain Product Portfolio 40
6.3 Cephalon Inc. 42
6.3.1 Overview 42
6.3.2 Pain Portfolio 42
6.3.3 Neuropathic Pain Product Portfolio 43
6.4 UCB S.A. 44
6.4.1 Overview 44
6.4.2 Pain Portfolio 44
6.4.3 Neuropathic Pain Portfolio 44
6.5 Newron Pharmaceuticals 45
6.5.1 Overview 45
6.5.2 Pain Portfolio 45
6.5.3 Neuropathic Pain Product Portfolio 46
6.6 EpiCept Corporation 47
6.6.1 Overview 47
6.6.2 Pain Portfolio 47
6.6.3 Neuropathic Pain Product Portfolio 47
6.7 GW Pharmaceuticals 48
6.7.1 Overview 48
6.7.2 Pain Portfolio 48
6.7.3 Neuropathic Pain Product Portfolio 49
6.8 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 50
6.8.1 Overview 50
6.8.2 Pain Portfolio 50
6.9 Avanir Pharmaceuticals 51
6.9.1 Overview 51
6.9.2 Pain Portfolio 51
6.9.3 Neuropathic Pain Product Portfolio 51
6.10 GlaxoSmithKline Plc. 51
6.10.1 Overview 51
6.10.2 Pain Portfolio 51
6.10.3 Neuropathic Pain Product Portfolio 52
6.11 AstraZeneca 52
6.11.1 Overview 52
6.11.2 Pain Portfolio 52
6.11.3 Neuropathic Pain Product Portfolio 53

7 Global Neuropathic Pain Market: Appendix 54
7.1 Market Definitions 54
7.2 Scope of Pipeline Research 54
7.3 Abbreviations 54
7.4 Research Methodology 55
7.4.1 Coverage 56
7.4.2 Secondary Research 56
7.4.3 Forecasting 57
7.4.4 Primary Research 60
7.4.5 Expert Panel Validation 60
7.5 Contact Us 60
7.6 Disclaimer 60
7.7 Sources 61

List of Table


Table 1: Neuropathic Pain, Global, Market Revenues, 20012009 7
Table 2: Neuropathic Pain, Global, Market Forecast, 20092016 7
Table 3: Major Marketed Products Comparison in the Neuropathic Pain Market, 2010 19
Table 4: Neuropathic Pain Therapeutics Most Promising Drugs under Clinical Development, 2010 23
Table 5: Neuropathic Pain Therapeutics Regulatory Filing and Phase III Clinical Pipeline, 2010 31
Table 6: Neuropathic Pain Therapeutics Phase II Clinical Pipeline, 2010 32
Table 7: Neuropathic Pain Therapeutics Phase I Clinical Pipeline, 2010 34
Table 8: Neuropathic Pain Therapeutics Preclinical Pipeline, 2010 35
Table 9: Neuropathic Pain Therapeutics Discovery Pipeline, 2010 35
Table 10: List of Discontinued Drugs for Neuropathic Pain, 2010 36
Table 11: NeurogesX Pain Marketed Products, 2010 40
Table 12: NeurogesX Pain Pipeline Products, 2010 40
Table 13: Cephalon Inc. Pain Marketed Products, 2010 42
Table 14: Cephalon Inc. Pain Pipeline Products, 2010 42
Table 15: UCB S.A. Pain Pipeline Products, 2010 44
Table 16: Newron Pharmaceuticals Pain Pipeline Products,2010 45
Table 17: EpiCept Corporation Pain Pipeline Products, 2010 47
Table 18: GW Pharmaceuticals Pain Marketed Products, 2010 48
Table 19: GW Pharmaceuticals Pain Pipeline Products, 2010 49
Table 20: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Pain Marketed Products, 2010 50
Table 21: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Pain Pipeline Products, 2010 50
Table 22: Avanir Pharmaceuticals Pain Pipeline Products, 2010 51
Table 23: GlaxoSmithKline plc. Pain Pipeline Products, 2010 52
Table 24: AstraZeneca Pain Pipeline Products, 2010 53

List of Chart


Figure 1: Neuropathic Pain, Global, Market Revenues, 20012009 6
Figure 2: Neuropathic Pain, Global, Market Forecast, 20092016 7
Figure 3: Opportunity and Unmet Need in the Neuropathic Pain Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Neuropathic Pain, 2010 12
Figure 5: Technology Trends Analytic Framework of the Neuropathic Pain Pipeline, 2010 21
Figure 6: Technology Trends Analytic Framework of the Neuropathic Pain Pipeline Description, 2010 22
Figure 7: Neuropathic Pain Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 29
Figure 8: Neuropathic Pain Pipeline by Phase of Clinical Development, 2010 30
Figure 9: Implications for Future Market Competition in the Neuropathic Pain Market, 2010 37
Figure 10: Neuropathic Pain Therapeutics Market Clinical Pipeline by Company, 2010 39
Figure 11: GlobalData Methodology 56
Figure 12: GlobalData Market Forecasting Model 59

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *